| Project/Area Number |
11670873
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
NAKAGAWA Keiichi The University of Tokyo, Radiology, Assistant Professor, 医学部・附属病院, 講師 (80188896)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TERAHARA Atsuro The University of Tokyo, Radiology Assistant Professor, 医学部・附属病院, 講師 (80237007)
ONOGI Yuzo The University of Tokyo, Medical Information, Associate, 医学部・附属病院, 助教授 (90233593)
AOKI Yukimasa The University of Tokyo, Radiology, Assistant Professor, 医学部・附属病院, 助教授 (40143474)
|
|---|
| Project Period (FY) |
1999 – 2001
|
| Project Status |
Completed (Fiscal Year 2001)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2001: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2000: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1999: ¥1,600,000 (Direct Cost: ¥1,600,000)
|
|---|
| Keywords | Radiosurgery / Thoracic malignancies / Megavoltage CT / Radiotherapy / Treatment planning / 3D-CRT |
|---|
| Research Abstract |
The aim of the study was to evaluate the efficacy of stereotactic radiosurgery (SRS) for thoracic tumors with megavoltage computed tomography (MVCT) from the point of view of symptom palliation as well as local control. MVCT-assisted positioning verification and real-time monitoring for a multi-leaf collimator (MVC) were used to enhance the accuracy of the thoracic SRS. Twenty-two thoracic tumors in 15 patients underwent the present treatment. All but one tumor were metastases from various primary malignancies. Eleven patients were symptomatic. The treatment site was the chest wall/pleura in 10 tumors, the lung field in 12 tumors. The median volume of the clinical target was 4.5 cc and the median peripheral dose was 20 Gy,for the lung tumors. For the chest wall/pleura tumors, the median volume of the clinical target was 40 cc and the median peripheral dose was 20 Gy. Conventional fractionated conformal radiation therapy (CRT) followed SRS in 10 tumors. Of twenty-one tumors eligible for evaluation, there were 13 CRs, 6PRs, and 2 NCs. Duration of local control ranged from 0.6 to 82 months with a median of 8 months. Immediate palliation was obtained in most symptomatic patients. Interstitial changes in the lung were limited. Autopsy performed for two patients revealed remarkable histologic effects with minimal injuries to the lung. The geometric accuracy of MVCT-assisted SRS appeared to enhance the clinical efficacy and safety of treatment to thoracic malignancies.
|
